Jemperli (dostarlimab-gxly)

P1/2, N=40, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> Oct 2029 | Trial primary completion date: Apr 2028 --> Aug 2028

P2, N=62, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

Treatment of LA HNSCC is multimodal and may include concomitant cisplatin-based chemoradiotherapy (CRT) or surgery; however, recurrence rates are high, and there is an unmet need for new treatments. The primary endpoint is event-free survival, with overall survival as a key secondary endpoint; safety and tolerability, pharmacokinetics, immunogenicity, biomarkers, and patient-reported outcomes will also be assessed. www.clinicaltrials.gov identifier is NCT06256588.

The analysis focuses on treatments that have demonstrated clinical benefit in advanced or recurrent disease, including pembrolizumab, dostarlimab, tisotumab vedotin, and mirvetuximab soravtansine. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.

Therapeutic progress in advanced endometrial cancer is mainly related to the first-line utilization of immunotherapy associated with chemotherapy, a strategy assessed in five randomized controlled trials, although at the moment, only dostarlimab is available in France...In second line, the combination of pembrolizumab and lenvatinib is the standard treatment if chemoimmunotherapy has not been used previously...The choice of the trial is guided by HER2 status in immunohistochemistry and results of new generation sequencing when available. The current trend towards the development of personalized medicine highlights the importance of pathological and molecular characterization of the tumor.

P1, N=21, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2027

In this prognostic study of patients with advanced NSCLC receiving ICI treatment, the fully automated biomarker Serial CTRS predicted OS more effectively than resource-intensive RECIST and TVC measurements using the same scans.

The increased mutational burden in MMRd tumors enhances their susceptibility to immune checkpoint inhibitors such as pembrolizumab and dostarlimab, which have demonstrated considerable efficacy and altered the treatment approach for patients with advanced or recurrent MMRd EC. This review highlights the significance of MMR testing in risk stratification, prognosis, and planning of personalized treatment, ultimately improving patient outcomes.

P1/2, N=45, Active, not recruiting, iOnctura | Recruiting --> Active, not recruiting

P2, N=66, Active, not recruiting, Meghan Shea | Recruiting --> Active, not recruiting

P2, N=45, Recruiting, Chang Gung Memorial Hospital

P1, N=97, Active, not recruiting, GlaxoSmithKline | Trial completion date: Mar 2025 --> Mar 2026